Literature DB >> 14634415

Salvage of sildenafil failures referred from primary care physicians.

Humphrey O Atiemo1, Michael J Szostak, Geoffrey N Sklar.   

Abstract

PURPOSE: Sildenafil citrate is an effective first line agent for most causes of erectile dysfunction. Primary care providers (PCPs) write the majority of these prescriptions and most failures of sildenafil therapy are subsequently referred to urologists for alternative therapies. Often it is concluded that the drug is ineffective when in actuality the failure is do to inadequate patient education. We examined patients referred from PCPs who were nonresponders to sildenafil therapy and attempted to convert them to responders through reeducation.
MATERIALS AND METHODS: In a 2-year period 253 sildenafil nonresponders were evaluated by the same urologist (GNS). Patient reeducation consisted of viewing a brief videotape, personal instruction and detailed instruction sheets for the patient and his partner. Outcome measures were obtained through patient self-reporting of the Sexual Health Inventory for Men and a global assessment question. Responders were identified as those who answered positively latter or had a statistical improvement in the score of the former.
RESULTS: Of the 253 patients reeducated 17 were excluded due to contraindications. Of the remaining nonresponders 41.5% achieved salvage with reeducation. Incorrect administration accounted for 81% of the failures. Average time with the physician was 12 minutes and 94% of the patients continued to respond at 26 months.
CONCLUSIONS: Approximately 40% of patients with sildenafil failures referred from PCPs can be converted to responders through reeducation. Incorrect drug administration was the most common reason for correctable failure. Reeducation can be done in an efficient manner. New package materials may improve sildenafil outcomes and compliance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634415     DOI: 10.1097/01.ju.0000096221.67967.ae

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Treating erectile dysfunction when PDE5 inhibitors fail.

Authors:  Chelsea N McMahon; Christopher J Smith; Ridwan Shabsigh
Journal:  BMJ       Date:  2006-03-11

2.  Effects of Ginkgo biloba extracts with mirodenafil on the relaxation of corpus cavernosal smooth muscle and the potassium channel activity of corporal smooth muscle cells.

Authors:  Jung Jun Kim; Deok Hyun Han; Soo Hyun Lim; Tae Hun Kim; Mee Ree Chae; Kyung Jin Chung; Sung Chul Kam; Ju-Hong Jeon; Jong Kwan Park; Sung Won Lee
Journal:  Asian J Androl       Date:  2011-04-11       Impact factor: 3.285

Review 3.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study.

Authors:  Pablo Garrido-Abad; Isabel Senra-Bravo; Celeste Manfredi; Esaú Fernández-Pascual; Estefanía Linares-Espinós; Manuel Fernández-Arjona; David Varillas-Delgado; Juan Ignacio Martínez-Salamanca
Journal:  Int J Impot Res       Date:  2021-01-22       Impact factor: 2.408

Review 5.  Erectile Dysfunction: A Primer for in Office Management.

Authors:  Samir Sami; Noah Stern; Andrew Di Pierdomenico; Brandon Katz; Gerald Brock
Journal:  Med Sci (Basel)       Date:  2019-08-29

Review 6.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

Review 7.  Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence.

Authors:  Konstantinos Hatzimouratidis
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

Review 8.  Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence.

Authors:  Giovanni Vanni Frajese; Flavio Pozzi; Gaetano Frajese
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.